WO2026003812 - ISOQUINOLINE DERIVATIVES AS ROCK INHIBITORS
National phase entry is expected:
Publication Number
WO/2026/003812
Publication Date
02.01.2026
International Application No.
PCT/IB2025/056590
International Filing Date
28.06.2025
Title **
[English]
ISOQUINOLINE DERIVATIVES AS ROCK INHIBITORS
[French]
DÉRIVÉS D'ISOQUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE ROCK
Applicants **
ALCON INC.
Inventors
KOPCZYNSKI, Casey Casimir
STURDIVANT, Jill Marie
MCCLURE, Michael Scott
JOSHI, Anjali Biren
Priority Data
63/666,009
28.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3457 | |
| EPO | Filing, Examination, Granting | 28742 | |
| Japan | Filing, Examination, Granting | 3264 | |
| South Korea | Filing, Examination, Granting | 4321 | |
| USA | Filing, Examination, Granting | 14540 |
Total:
54,324
Contact Us
Abstract[English]
Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).[French]
L'invention concerne des composés comprenant une formule de 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yI)benzyl adamantane carboxylate (p. ex. des composés de formule (I)) ou un sel pharmaceutiquement acceptable de ceux-ci. Ces composés sont utiles pour réduire la pression intraoculaire et pour traiter le glaucome ou l'hypertension oculaire. Formule (I).